<?xml version="1.0" encoding="UTF-8" standalone="yes"?><PatentFamilySummaryOutputs><PatentFamilySummaryOutput id="502975"><Title>Besylate salt form of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-(4-(6-(morpholin-4-yl-methyl)-pyridin-3-yl)-naphthalen-1-yl)-urea and polymorphs thereof</Title><Assignee>Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharma GmbH &amp; Co KG</Assignee><Familymembers>WO-2007109434</Familymembers><PatentNumber>WO-2007109434</PatentNumber><Indication>Inflammatory disease; Autoimmune disease; Cancer</Indication><Action>p38 MAP kinase inhibitor; TNF alpha synthesis inhibitor</Action></PatentFamilySummaryOutput></PatentFamilySummaryOutputs>